Appendiceal diverticulum perforation during chemotherapy with bevacizumab for colorectal cancer: A case report

DOI IR
  • Nakamura Hiroki
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Kudo Shin-ei
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Wakamura Kunihiko
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Baba Toshiyuki
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Miyachi Hideyuki
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Kaneshiro Miyuki
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Takehara Yusuke
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Shimada Shoji
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Nakahara Kenta
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Seki Junichi
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Sawada Naruhiko
    Digestive Disease Center, Showa University Northern Yokohama Hospital
  • Nemoto Tetsuo
    Pathology and Laboratory Medicine, Showa University Northern Yokohama Hospital
  • Ishida Fumio
    Digestive Disease Center, Showa University Northern Yokohama Hospital

Bibliographic Information

Other Title
  • ベバシズマブを併用した化学療法中に虫垂憩室穿孔を来した大腸癌の一例

Search this article

Abstract

Bevacizumab is a vascular endothelial growth factor （VEGF） inhibitor. It inhibits angiogenesis, tumor growth, and metastasis and is, therefore, recommended for the first-line chemotherapy against colorectal cancer. Although bowel perforation is a rare, it is a severe adverse effect of VEGF inhibitor therapy. In addition to a literature review, we report a rare case of appendiceal perforation secondary to an appendicular diverticulum in a patient who received chemotherapy in combination with bevacizumab. In these cases, continuing chemotherapy and selecting the optimal drug regimen may be challenging; however, chemotherapy resumption at an appropriate time may prolong survival.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top